Lipella Pharmaceuticals Net Worth
Lipella Pharmaceuticals Net Worth Breakdown | LIPO |
Lipella Pharmaceuticals Net Worth Analysis
Lipella Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Lipella Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Lipella Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Lipella Pharmaceuticals' net worth analysis. One common approach is to calculate Lipella Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Lipella Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Lipella Pharmaceuticals' net worth. This approach calculates the present value of Lipella Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Lipella Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Lipella Pharmaceuticals' net worth. This involves comparing Lipella Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Lipella Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Lipella Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lipella Pharmaceuticals' net worth research are outlined below:
| Lipella Pharmaceuticals generated a negative expected return over the last 90 days | |
| Lipella Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 449.62 K. Net Loss for the year was (4.62 M) with loss before overhead, payroll, taxes, and interest of (2.36 M). | |
| Lipella Pharmaceuticals generates negative cash flow from operations | |
| About 29.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from investing.com: Lipella Pharmaceuticals faces potential Nasdaq delisting |
Lipella Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lipella Pharmaceuticals Common. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lipella Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Lipella Pharmaceuticals Target Price Consensus
Lipella target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Lipella Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Buy |
Most Lipella analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Lipella stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Lipella Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationLipella Pharmaceuticals Target Price Projection
Lipella Pharmaceuticals' current and average target prices are 2.85 and 16.00, respectively. The current price of Lipella Pharmaceuticals is the price at which Lipella Pharmaceuticals Common is currently trading. On the other hand, Lipella Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Lipella Pharmaceuticals Market Quote on 19th of January 2025
Target Price
Analyst Consensus On Lipella Pharmaceuticals Target Price
Know Lipella Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lipella Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lipella Pharmaceuticals Common backward and forwards among themselves. Lipella Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Lipella Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Vanguard Group Inc | 2024-06-30 | 34.5 K | Geode Capital Management, Llc | 2024-06-30 | 26 K | Tower Research Capital Llc | 2024-06-30 | 7.7 K | Bank Of America Corp | 2024-06-30 | 46.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Sabby Management Llc | 2024-09-30 | 0.0 | Two Sigma Investments Llc | 2024-09-30 | 0.0 | Fmr Inc | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-09-30 | 0.0 | Hrt Financial Llc | 2024-06-30 | 0.0 |
Follow Lipella Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.57 M.Market Cap |
|
Project Lipella Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.48) | (1.41) | |
| Return On Capital Employed | (1.71) | (1.62) | |
| Return On Assets | (1.48) | (1.41) | |
| Return On Equity | (1.69) | (1.60) |
When accessing Lipella Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Lipella Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lipella Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Lipella Pharmaceuticals' management efficiency
Lipella Pharmaceuticals has return on total asset (ROA) of (0.9377) % which means that it has lost $0.9377 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7156) %, meaning that it created substantial loss on money invested by shareholders. Lipella Pharmaceuticals' management efficiency ratios could be used to measure how well Lipella Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of January 2025, Return On Tangible Assets is likely to grow to -1.41. In addition to that, Return On Capital Employed is likely to grow to -1.62. At this time, Lipella Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 19th of January 2025, Other Current Assets is likely to grow to about 174.6 K, while Total Assets are likely to drop about 2.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.77 | 3.96 | |
| Tangible Book Value Per Share | 3.77 | 3.96 | |
| Enterprise Value Over EBITDA | (0.74) | (0.70) | |
| Price Book Value Ratio | 1.75 | 1.84 | |
| Enterprise Value Multiple | (0.74) | (0.70) | |
| Price Fair Value | 1.75 | 1.84 | |
| Enterprise Value | 2.7 M | 2.5 M |
Effective leadership at Lipella Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Enterprise Value Revenue 4.4723 | Revenue | Quarterly Revenue Growth 0.279 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lipella Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lipella Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lipella Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lipella Pharmaceuticals Corporate Filings
F4 | 17th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 16th of January 2025 Other Reports | ViewVerify | |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 7th of January 2025 Other Reports | ViewVerify |
Lipella Pharmaceuticals Earnings per Share Projection vs Actual
Lipella Pharmaceuticals Corporate Executives
Elected by the shareholders, the Lipella Pharmaceuticals' board of directors comprises two types of representatives: Lipella Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipella. The board's role is to monitor Lipella Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lipella Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipella Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael MD | Chief CoFounder | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipella Pharmaceuticals Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.88) | Revenue Per Share | Quarterly Revenue Growth 0.279 | Return On Assets | Return On Equity |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.